• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,741.82 238.22
( 0.31%)
Global Indices
Nasdaq
52,357.11 -589.04
(-1.11%)
Dow Jones
7,503.65 -21.20
(-0.28%)
Hang Seng
67,966.49 1,147.44
(1.72%)
Nikkei 225
10,472.08 -16.96
(-0.16%)
Forex
USD-INR
95.15 -0.21
(-0.22%)
EUR-INR
108.73 -0.26
(-0.24%)
GBP-INR
127.27 -0.11
(-0.09%)
JPY-INR
0.59 0.00
(-0.14%)

EQUITY - MARKET SCREENER

Jubilant Pharmova Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
530019
INE700A01033
145.1556811
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
JUBLPHARMA
492.84
15466.44
EPS(TTM)
Face Value()
Div & Yield %
1.97
1
0.51
 

Ashok Leyland gains after June 2026 sales rise 25% YoY to 19,194 units
Jul 01,2026
Total medium and heavy commercial vehicle (M&HCV) sales rose 23.67% YoY to 12,156 units, while light commercial vehicle (LCV) sales increased 27.87% to 7,038 units in June 2026.

In the domestic market, total vehicle sales climbed 26.28% YoY to 17,912 units from 14,184 units a year earlier. Domestic M&HCV sales grew 25.50% to 11,131 units, while domestic LCV sales advanced 27.58% to 6,781 units.

Ashok Leyland is involved in the manufacture and sale of a broad range of commercial vehicles and also makes engines for industrial and marine applications, as well as forgings and castings.

For the quarter ended 31 March 2026, Ashok Leyland reported a 14.21% year-on-year increase in consolidated net profit to Rs 1,290.70 crore, while revenue from operations rose 17.09% to Rs 17,138.90 crore.